PSIVIDA CORP. (NASDAQ:PSDV) Files An 8-K Other Events
On June22, 2017, pSivida Corp. issued a press release announcing
that the Company has submitted a Marketing Authorization
Application to the European Medicines Agency, seeking approval to
market the Companys Durasert three-year treatment for posterior
segment uveitis in the European Union. A copy of the press
release making such announcement is filed as Exhibit 99.1 hereto.
|Financial Statements and Exhibits|
|99.1||Press release dated June22, 2017|
pSivida Corp. ExhibitEX-99.1 2 d416927dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in the European Union WATERTOWN,…To view the full exhibit click
here About PSIVIDA CORP. (NASDAQ:PSDV)
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.